Lucid Diagnostics raises $24.6M in preferred & debt; 4Q22 revenue $0.1M, net loss $14.9M

Lucid Diagnostics Inc.

Secured $13.6M from Series A preferred stock and $11.1M senior secured convertible note, extending cash runway into 2024.
4Q22 EsoGuard test volume 1,174, up 8% sequentially and 288% YoY; projects ~1,600 tests in 1Q23.
Signed in-network agreement with MultiPlan, expanding access to ~60 million consumers.
GAAP net loss $14.9M ($0.47/share) in 4Q22; non-GAAP adjusted loss $10.6M ($0.33/share).
Cash and equivalents $22.5M at Dec 31, 2022, bolstered by subsequent financings.

item 1.01 item 2.02 item 2.03 item 3.02 item 3.03 item 7.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.